HER2低表达乳腺癌的临床研究进展

doi:10.11904/j.issn.1002-3070.2022.06.015

Abstract

Abstract: Breast cancer is the malignant tumor with the highest incidence in the world,which seriously affects women′s health.As an important therapeutic target for breast cancer,human epidermal growth factor receptor 2(HER2)has improved the prognosis of these patients.In the past diagnosis and treatment process,breast cancer with low HER2 expression was classified as HER2 negative breast cancer.With the deepening research,it is found that breast cancer patients with HER2 low expression have some differences in clinicopathological and molecular biological characteristics,as well as survival prognosis,and are difficult to benefit from traditional anti-HER2 therapy.Several studies have explored the efficacy and safety of antibody-drug conjugates(ADCs)and other new drugs in breast cancer with low HER2 expression.This article will review the research progress of breast cancer with low HER2 expression.

Key words: Breast cancer, HER2, Low expression, Research progress

CLC Number:

R737.9

WU Ruiyue, ZHU Kaili, YANG Jingru, LING Xiaoling. Clinical research progress of breast cancer with low HER2 expression[J]. Journal of Practical Oncology, 2022, 36(6): 570-575.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2022.06.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2022/V36/I6/570

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Di FioreP,Pierce JH,Kraus MH,et al.ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells[J].S cience,1987,237(4811):178-182.
3 钟锦绣,李亚梅,关晏星.乳腺癌HER-2胞外配体结合区靶点治疗的研究进展[J].中国肿瘤临床,2013,40(17):1076-1079.
4 Franchet C,Djerroudi L,Maran-Gonzalez A,et al.2021 update of the GEFPICS′ recommendations for HER2 status assessment in invasive breast cancer in France[J].Ann Pathol,2021,41(6):507-520.
5 孙正魁,江泽飞.2022版《中国临床肿瘤学会乳腺癌诊疗指南》更新解读[J].中国肿瘤外科杂志,2022,14(3):212-218.
6 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2021版)[J].中国癌症杂志,2021,31(10):954-1040.
7 Tarantino P,Hamilton E,Tolaney SM,et al.HER2-low breast cancer:pathological and clinical landscape[J].J Clin Oncol,2020,38(17):1951-1962.
8 Denkert C,Seither F,Schneeweiss A,et al.Clinical and molecular characteristics of HER2-low-positive breast cancer:pooled analysis of individual patient data from four prospective,neoadjuvant clinical trials[J].Lancet Oncol,2021,22(8):1151-1161.
9 Agostinetto E,Rediti M,Fimereli D,et al.HER2-low breast cancer:molecular characteristics and progosis[J].Cancers,2021,13(11):2824.
10 Schettini F,Chic N,Brasó-Maristany F,et al.Clinical,pathological,and PAM50 gene expression features of HER2-low breast cancer[J].NPJ Breast Cancer,2021,7(1):1.
11 Modi S,Park H,Murthy RK,et al.Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer:results from a phase Ib study[J]J Clin Oncol,2020,38(17):1887-1896.
12 Wolff AC,Hammond MEH,Allison KH,et al.Human epidermal growth factor receptor 2 testing in breast cancer:american society of clinical oncology/college of american pathologists clinical practice guideline focused update[J].J Clin Oncol,2018,36(20):2105-2122.
13 Dieras V,Deluche E,Lusque A,et al.Trastuzumab deruxtecan(T-DXd)for advanced breast cancer patients(ABC),regardless HER2 status:a phase Ⅱ study with biomarkers analysis(AISY)[J].Cancer Res,2022,82(4):67-72.
14 詹晓芬,王少洪,况丽平,等.标本离体固定时间对荧光原位杂交技术检测乳腺润性导管癌HER2基因的影响[J].广西医学,2019,41(8):996-998.
15 Dentro SC,Leshchiner I,Haase K,et al.Characterizing genetic intra-tumor heterogeneity across 2,658 human cancergenomes[J].Cell,2021,184(8):2239-2254.
16 Marchiò C,Annaratone L,Marques A,et al.Evolving concepts in HER2 evaluation in breast cancer:Heterogeneity,HER2-low carcinomas and byond[J].Semin Cancer Biol,2021,72:123-135.
17 Miglietta F,Griguolo G,Bottosso M,et al.Evolution of HER2-low expression from primary to recurrent breast cncer[J].NPJ Breast Cancer,2021,7(1):137.
18 Miglietta F,Griguolo G,Bottosso M,et al.HER2-low-positive breast cancer:evolution from primary tumor to residual disease after neoadjuvant treatment[J].NPJ Breast Cancer,2022,8(1):66.
19 Allison KH,Wolff AC.ERBB2-low breast cancer-is it a fact or fiction,and do we have the right assay[J].JAMA Oncol,2022,8(4):610-611.
20 Grassini D,Cascardi E,Sarotto I,et al.Unusual patterns of HER2 expression in breast cancer:insights and prspectives[J].Pathobiology,2022,89(5):278-296.
21 耿强,钱晓龙,付丽.乳腺癌HER-2检测的概况与进展[J].中国肿瘤临床,2014,41(10):671-674.
22 Asensio AF,Sierra LM,Montes-Bayón M,et al.Sensitive determination of the human epidermal growth factor receptor 2(HER2)by immuno-polymerase chain reaction with inductively coupled plasma-mass spectrometr detection[J].Anal Chim Acta,2019,1090:39-46.
23 Fernandez AI,Liu M,Bellizzi A,et al.Examination of low ERBB2 protein expression in brast cancer tissue[J].JAMA Oncol,2022,8(4):1-4.
24 Zhang G,Ren C,Li C,et al.Distinct clinical and somatic mutational features of breast tumors with high-,low-,or non-expressing human epidermal growth fator receptor 2 status[J].BMC Med,2022,20(1):142.
25 Zhang H,Katerji H,Turner BM,et al.HER2-low breast cancers:incidence,HER2 staining patterns,clinicopathologic features,MammaPrint and BluePrint genomi profiles[J].Mod Pathol,Inc,2022,35(8):1075-1082.
26 Jacot W,Maran-Gonzalez A,Massol O,et al.Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlationwith other biomarkers[J].Cancers,2021,13(23):6059.
27 Pondé N,Aftimos P,Piccart M.Antibody-drug conjugates in breast cancer:a comprehensve review[J].Curr Treat Options Oncol,2019,20(5):37.
28 Xu ZY,Guo DD,Jiang ZL,et al.Novel HER2-targeting antibody-drug conjugates of Trastuzumab beyond T-DM1 in breast cancer:Trastuzumab Deruxtecan(DS-8201a)and(Vic-)Trastuzumab Ducarmazine(SYD985)[J].Eur J Med Chem,2019,183:111682.
29 Press MF,Finn RS,Cameron D,et al.HER2 gene amplification,HER2 and epidermal growth factor receptor mRNA and protein expression,and lapatinib efficacy in women with metastatic brast cancer[J].Clin Cancer Res,2008,14(23):7861-7870.
30 Modi S,Jacot W,Yamashita T,et al.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J].N Engl J Med,2022,387(1):9-20.
31 Banerji U,Herpen CML,Saura C,et al.Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer:a phase 1 dose-escalation and dos-expansion study[J].Lancet Oncol,2019,20(8):1124-1135.
32 Xu Y,Wang Y,Gong J,et al.Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive avanced solid tumors[J].Gastric Cancer,2021,24(4):913-925.
33 Li L,Xu MZ,Wang L,et al.Conjugating MMAE to a novel anti-HER2 antibody for selective targeted dlivery[J].Eur Rev Med Pharmacol Sci,2020,24(24):12929-12937.
34 Shi F,Liu Y,Zhou X,et al.Disitamab vedotin:a novel antibody-drug conugates for cancer therapy[J].Drug Deliv,2022,29(1):1335-1344.
35 Schmid P,Im SA,Armstrong A,et al.BEGONIA:Phase 1b/2 study of durvalumab(D)combinations in locally advanced/metastatic triple-negative breast cancer(TNBC)-initial results from arm 1,d+paclitaxel(P),and arm 6,d+trasuzumab deruxtecan(T-DXd)[J].J Clin Oncol,2021,39(15):15-21.
36 Hamilton EP,Shapiro CL,Boni V,et al.Primary analysis from DS8201-A-U105:a 2-part,open label,phase Ib trial assessing trastuzumab deruxtecan(T-DXd)with nivolumab(nivo)in patients(pts)with HER2-xpressing advanced breast cancer[J].Ann Oncol,2022,33:194-223.
37 Segués A,Huang S,Sijts A,et al.Opportunities and challenges ofbi-specific antibodies[J].Int Rev Cell Mol Biol,2022,369:45-70.
38 Zhang J,Ji D,Cai L,et al.First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with HER2-positive metastatic breast cancer:rsults from a phase I study[J].Clin Cancer Res,2022,28(4):618-628.
39 Bartsch R,Bergen E.ASCO 2018:highlights in HER2-positive metastatic breast cancer[J].Memo,2018,11(4):280-283.
40 Akbari V,Chou CP,Abedi D.New insights into affinity proteins for HER2-targeted therapy:beyond trastuzumab[J].Biochim Biophys Acta Rev Cancer,2020,1874(2):1888448.
41 Hamblett KJ,Hammond PW,Barnscher SD,et al.ZW49,a HER2-targeted biparatopic antibody-drug conjugate for the tratment of HER2-expressing cancers[J].Cancer Res,2018,78(13):69-73.
42 Burstein HJ.The distinctive nature of HER2-positive breast cancers[J].N Engl J Med,2005,353(16):1652-1654.
43 Schneble EJ,Berry JS,Trappey FA,et al.The HER2 peptide nelipepimut-S(E75)vaccine(NeuVax^TM)in breast cancer patients at risk for recurrence:correlation of immunlogic data with clinical response[J].Immunotherapy,2014,6(5):519-531.
44 Gall VA,Philips AV,Qiao N,et al.Trastuzumab increases HER2 uptake and crss-presentation by dendritic cells[J].Cancer Res,2017,77(19):5374-5383.
45 Mittendorf EA,Clifton GT,Holmes JP,et al.Final report of the phase Ⅰ/Ⅱ clinical trial of the E75(nelipepimut-S)vaccine with booster inoculations to prevent disease recurrenc in high-risk breast cancer patients[J].Ann Oncol,2014,25(9):1735-1742.
46 Mittendorf EA,Lu B,Melisko M,et al.Efficacy and safety analysis of nelipepimut-s vaccine to prevent breast cancer recurrence:a randomized,multicnter,phase Ⅲ Clinical trial[J].Clin Cancer Res,2019,25(14):4248-4254.

[1]	JIAO Chong, SHI Yuxin, XU Haoyi, MA Binlin, DONG Chao. Study of the effect of metformin on prognosis of different subtypes of breast cancer patients with type 2 diabetes mellitus [J]. Journal of Practical Oncology, 2022, 36(6): 531-537.
[2]	CHEN Junhui, LIU Siyu, HE Changjun. Research progress of RUNX1 in lung cancer [J]. Journal of Practical Oncology, 2022, 36(6): 576-579.
[3]	WANG Xinghan, LV Yalei. Mechanisms of trastuzumab resistance and post-resistance treatment strategies in HER2-positive breast cancer [J]. Journal of Practical Oncology, 2022, 36(5): 445-451.
[4]	KANG Ziman, YANG Danlin, SUN Jiannan. Progress of breast MRI image texture analysis in breast cancer [J]. Journal of Practical Oncology, 2022, 36(5): 472-476.
[5]	LI Zhihui, LI Zhigao. Research progress of T-DM1 in treatment of HER2 positive breast cancer [J]. Journal of Practical Oncology, 2022, 36(5): 477-482.
[6]	CHEN Jiayi, BAI Yanling. The influence of body mass index and body position fixation in breast cancer patients post-operative intensity modulated radiation therapy setup error [J]. Journal of Practical Oncology, 2022, 36(4): 327-331.
[7]	ZHAO Danni, YAN Shi, CAI Li. Research progress on follow - up and drug side effect management strategy of breast cancer [J]. Journal of Practical Oncology, 2022, 36(4): 369-373.
[8]	ZONG Yuxuan, PANG Da. Research progress of heat shock protein 90 in the occurrence,development and treatment of breast cancer [J]. Journal of Practical Oncology, 2022, 36(4): 381-385.
[9]	YANG Zihan, XU Shouping, PANG Da. Characteristics of breast cancer metastases to outer triangle tissue and its influencing factors [J]. Journal of Practical Oncology, 2022, 36(3): 226-232.
[10]	HE Weidan, LI Zhigao. FSIP1 promotes migration and invasion of breast cancer cells and leads to poor prognosis of patients [J]. Journal of Practical Oncology, 2022, 36(3): 233-238.
[11]	LIU Xinxin, YAO Xinhui, SUN Yuefeng, MIU Meiqi, CHEN Jing. Research progress in the role of chemokine CCL20 in breast cancer microenvironment [J]. Journal of Practical Oncology, 2022, 36(3): 250-254.
[12]	YANG Shuya, LIU Wenhui, LUO Naixiang. Research status and application prospect of UCA1 in breast cancer [J]. Journal of Practical Oncology, 2022, 36(3): 263-267.
[13]	LIU Wanying, PANG Da. Research progress on the mechanism of metastasis in invasive micropapillary carcinoma of the breast [J]. Journal of Practical Oncology, 2022, 36(3): 268-272.
[14]	SUN Yuanyuan, ZHANG Ningzhi, CAO Mengru. The mechanism and treatment progress of breast cancer lung metastasis [J]. Journal of Practical Oncology, 2022, 36(2): 173-177.
[15]	HOU Jianxun, WANG Hongbin. Research progress on the influence of exosomes in the integration of breast cancer diagnosis and treatment [J]. Journal of Practical Oncology, 2022, 36(2): 178-182.

Clinical research progress of breast cancer with low HER2 expression

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments